FAST NEWS: Ascletis Pharma’s Cancer Drug Eyes U.S. with New Drug Application
The latest: Ascletis Pharma Inc. (1672.HK) announced it has filed an Investigational New Drug (IND) application in the U.S. for its self-house developed oral PD-L1 small molecule inhibitor, ASC61, for the…
RELATED ARTICLES
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG
-
FAST NEWS: Ascletis Pharma’s loss narrows as core product sales surge
1672.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Fosun Pharma, CanSino take different paths as Covid lift fade
2196.HK 6185.HK
-
Debt pressures cast cloud over Fosun Pharma results
2196.HK 600196.SHG
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
Discover hidden China stock gems in our weekly newsletter